Evidence map›Paper›PMID 35974187›Full record

ArticleCarcinogenesis2022

Fenretinide combines perturbation of signaling kinases, cell-extracellular matrix interactions and matrix metalloproteinase activation to inhibit invasion in oral squamous cell carcinoma cells.

Daren Wang, Ping Pei, Fortune F Shea, Caroline Bissonnette, Kari Nieto, Corrine Din, Yayuan Liu, Steven P Schwendeman, Yan X Lin, Richard Spinney and 1 more

Open access · greenAbstract read
In one paragraph

Article in Carcinogenesis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Unraveling the Causal Linkages ofBioMed research international · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Novel Tryptanthrin Derivatives with Selectivity asMolecules (Basel, Switzerland) · 2023
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Daren WangDivision of Oral Maxillofacial Pathology & Radiology, College of Dentistry, The Ohio State University, Columbus, OH, USA.ORCID 0000-0002-5621-6295
Ping PeiDivision of Oral Maxillofacial Pathology & Radiology, College of Dentistry, The Ohio State University, Columbus, OH, USA.
Fortune F SheaDivision of Oral Maxillofacial Pathology & Radiology, College of Dentistry, The Ohio State University, Columbus, OH, USA.
Caroline BissonnetteDivision of Oral Maxillofacial Pathology & Radiology, College of Dentistry, The Ohio State University, Columbus, OH, USA.
Kari NietoDepartment of Pharmaceutical Sciences and the Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA.
Corrine DinDepartment of Pharmaceutical Sciences and the Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA.
Yayuan LiuDepartment of Pharmaceutical Sciences and the Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA.
Steven P SchwendemanDepartment of Pharmaceutical Sciences and the Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA.
Yan X LinDepartment of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, USA.ORCID 0000-0003-2956-6940
Richard SpinneyDepartment of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, USA.
Susan R MalleryDivision of Oral Maxillofacial Pathology & Radiology, College of Dentistry, The Ohio State University, Columbus, OH, USA.
The Ohio State University · USUniversity of Michigan · US

Funding

Formulation, Evaluation, and Phase 0 Trial of Nanoparticle Releasing Oral Thin Film for OSCC ChemopreventionR01CA258757 · NCI · OHIO STATE UNIVERSITY · PI Susan R Mallery · 2022 to 2026
$3.0M
Assessment of Chemopreventive Effects of a Mucoadhesive Fenretinide Patch on Premalignant Oral Epithelial LesionsR01CA227273 · NCI · OHIO STATE UNIVERSITY · PI MALLERY, SUSAN R · 2019 to 2024
$2.8M
Cellular Biotechnology Training Program (CBTP) - Years 31-35T32GM145304 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Guizhi Zhu · 2022 to 2026
$2.6M
Secondary Chemoprevention of Oral Cancer by Locally Delivered AgentsR01CA211611 · NCI · OHIO STATE UNIVERSITY · PI MALLERY, SUSAN R · 2017 to 2021
$1.8M
NCI NIH HHS R01 CA211611NCI NIH HHS R01 CA227273NCI NIH HHS R01 CA258757NIGMS NIH HHS T32 GM145304
6 · The paper itself

Abstract

Basement membrane invasion defines malignant transformation of surface premalignancy. Treatment of oral squamous cell carcinoma (OSCC) cells with the synthetic vitamin A derivative, fenretinide (4HPR), induces numerous cancer-preventive effects including suppression of basement membrane invasion, elimination of anchorage-independent growth, disruption of actin cytoskeletal components and inhibition of the invasion-enabling focal adhesive kinase. The purpose of this study was to elucidate 4HPR's effects on additional invasion-relevant mechanisms including matrix metalloproteinase (MMP) activation and function, cell-extracellular matrix (ECM) attachments and interaction with a kinase that is essential for the epithelial-myoepithelial transformation i.e. c-Jun NH2-terminal kinase (JNK). Our data revealed that 4HPR binds with high affinity to the ATP-binding site of all three JNK isoforms with concurrent suppression of kinase function. Additional studies showed 4HPR treatment inhibited both OSCC cell-ECM adhesion and MMP activation and function. JNK downregulation and induced expression studies confirmed that the JNK3 isoform conveyed that largest impact on OSCC migration and invasion. Biodegradable polymeric implants formulated to preserve 4HPR's function and bioavailability were employed to assess 4HPR's chemopreventive impact on an OSCC tumor induction model. These studies revealed 4HPR local delivery significantly inhibited OSCC tumor size, mitotic indices and expression of the endothelial marker, erythroblast transformation-specific-related gene with concurrent increases in tumor apoptosis (cleaved caspase-3). Collectively, these data show that 4HPR suppresses invasion at multiple sites including 'outside-in' signaling, cell-ECM interactions and suppression of MMPs. These functions are also essential for physiologic function. Regulation is therefore essential and reinforces the pharmacologic advantage of local delivery chemopreventive formulations. .

Indexed as

Carcinoma, Squamous CellFenretinideHead and Neck NeoplasmsMouth NeoplasmsActinsAdenosine TriphosphateCaspase 3Cell Line, TumorExtracellular MatrixHumansMatrix MetalloproteinasesNeoplasm InvasivenessSquamous Cell Carcinoma of Head and NeckVitamin AActinsAdenosine TriphosphateCaspase 3FenretinideMatrix MetalloproteinasesVitamin A

Identifiers

PMID35974187
PMCPMC9587683
OpenAlexW4292171089

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.